ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

MTOR Inhibition Acts Directly on Endothelial Cells to Induce Contact-Independent Immune-Modulation of Allo-Specific T Cell Activation

H. Xu, L. Wang, V. A. Bendersky, Q. Gao, Q. Li, A. D. Kirk, H. Xu

Duke University School of Medicine, Durham, NC

Meeting: 2022 American Transplant Congress

Abstract number: 171

Keywords: Endothelial cells, Immunogenicity, Rapamycin, T cell activation

Topic: Basic Science » Basic Science » 12 - Immunosuppression & Tolerance: Preclinical & Translational Studies

Session Information

Session Name: Immunosuppression and Tolerance: Preclinical and Translational Studies

Session Type: Rapid Fire Oral Abstract

Date: Sunday, June 5, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 6:10pm-6:20pm

Location: Hynes Ballroom A

*Purpose: Endothelial cells (ECs) form a barrier between vascularized organ allografts and host immunity and are known to provoke alloimmune responses. The mTOR inhibitor rapamycin is known to effectively attenuate alloimmunity, a trait that has been attributed to its action on T cells. However, given the ubiquity of the mTOR pathway, we hypothesized that rapamycin could also perhaps act directly on ECs, altering T-cell immunity through a direct effect on donor ECs.

*Methods: Human ECs were studied with and without exposure to rapamycin for cytokine release using a multiplex assay, and T cell responses to ECs were assayed using an intracellular cytokine staining (ICCS) and a VPD450-dilution based T cell proliferation assay. A transwell system was used to evaluate the role of EC-T cell contact in observed responses. RNA-sequencing was performed on naïve and rapamycin-pretreated ECs to assess alterations in transcriptomic profiles. Mouse heart transplants were used to assess effects of rapamycin pre-treatment on donors.

*Results: Unlike untreated ECs, rapamycin-pretreated ECs significantly suppressed T-cell proliferation (p<0.0001). The suppressive effect persisted (p<0.0001) despite transwell separation between ECs and responding T cells in MLR. Rapamycin-pretreated ECs made less IL-6, IL-8, and MCP-1 following TNF-a/IFN-g stimulation, but exogenous IL-6/IL-8/MCP-1 did not reverse the suppressive effect on T-cell proliferation. Rapamycin-pretreated ECs upregulated PD-1 ligand expression, though PD-1 blockade failed to restore T cell proliferation. The effect of rapamycin-treated ECs was partial on polyfunctional allospecific memory CD8+ T cells. Medium collected from control or rapamycin-pretreated ECs was size-filtered based on molecular weights and tested in MLR. We demonstrated that molecule(s) eliciting immunosuppressive effects were above 10 kDa. RNA-sequencing analysis revealed a downregulation of genes in pathways associated with cytokine/chemokines, cell adhesion, NF-kB, and transendothelial migration. Pre-exposing donor hearts to rapamycin improved the effect of B7 costimulation blockade, prolonging the survival of heart allografts in an MHC mismatched murine model.

*Conclusions: mTOR blockade down-regulates genes in ECs involving in pathways associated with immune-recognition, adhesion, presentation, and costimulation, and reduces the capacity of ECs to stimulate allospecific T cell immune-responses independent of PD-1/PD-ligand interaction, acting in a contact-independent manner. Pre-treatment of a donor with rapamycin synergizes with CTLA4Ig, prolonging cardiac allograft survival in MHC-mismatched mice. This finding implies that in addition to its effect on recipient immunity, rapamycin acts directly on the donor organ, lessing its immunogenicity.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Xu H, Wang L, Bendersky VA, Gao Q, Li Q, Kirk AD, Xu H. MTOR Inhibition Acts Directly on Endothelial Cells to Induce Contact-Independent Immune-Modulation of Allo-Specific T Cell Activation [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/mtor-inhibition-acts-directly-on-endothelial-cells-to-induce-contact-independent-immune-modulation-of-allo-specific-t-cell-activation/. Accessed June 6, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences